15714563 false Consultancy 2024-05-11 2025-05-31 http://www.companieshouse.gov.uk/2024-05-10 http://www.companieshouse.gov.uk/cd:CompanySecretary1 2024-05-11 2025-05-31 http://www.companieshouse.gov.uk/cd:Director1 2024-05-11 2025-05-31 http://www.companieshouse.gov.uk/pt:ShareCapital 2025-05-31 http://www.companieshouse.gov.uk/cd:OrdinaryShareClass1 2024-05-11 2025-05-31 http://www.companieshouse.gov.uk/pt:ToolsEquipment 2025-05-31 http://www.companieshouse.gov.uk/cd:RegisteredOffice 2024-05-11 2025-05-31 http://www.companieshouse.gov.uk/cd:AuditExemptWithAccountantsReport 2024-05-11 2025-05-31 http://www.companieshouse.gov.uk/pt:CurrentFinancialInstruments 2025-05-31 http://www.companieshouse.gov.uk/2024-05-11 2025-05-31 http://www.companieshouse.gov.uk/cd:FRS102 2024-05-11 2025-05-31 http://www.companieshouse.gov.uk/2025-05-31 http://www.companieshouse.gov.uk/cd:FullAccounts 2024-05-11 2025-05-31 http://www.companieshouse.gov.uk/cd:PrivateLimitedCompanyLtd 2024-05-11 2025-05-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 15714563
Pharma4orce Ltd
ACCOUNTS
FOR THE 386 DAY PERIOD ENDED 31/05/2025
Prepared By:
Anstee Gorst
Unit 4 Eaton Court
Colmworth Business Park
Eaton Socon
Cambridgeshire
PE19 8ER

Pharma4orce Ltd

ACCOUNTS
FOR THE 386 DAY PERIOD ENDED 31/05/2025
DIRECTORS
Richard Bell
SECRETARY
Barbara Bell
REGISTERED OFFICE
The Village Farmhouse
6 Village Road, Cockayne Hatley
Sandy
Bedfordshire
SG19 2EE
COMPANY DETAILS
Private company limited by shares registered in EW - England and Wales, registered number 15714563
ACCOUNTANTS
Anstee Gorst
Unit 4 Eaton Court
Colmworth Business Park
Eaton Socon
Cambridgeshire
PE19 8ER

Pharma4orce Ltd

ACCOUNTS
FOR THE 386 DAY PERIOD ENDED 31/05/2025
CONTENTS |  |
|  | Page
Directors' Report |  | -
Accountants' Report |  | -
Statement Of Comprehensive Income |  | -
Balance Sheet |  | 3
Notes To The Accounts |  | 4
The following do not form part of the statutory financial statements: |  |
Trading And Profit And Loss Account |  | -
Profit And Loss Account Summaries |  | -

Pharma4orce Ltd

BALANCE SHEET AT 31/05/2025
|  |  |  |  |  | 2025
|  | Notes |  |  |  | £
FIXED ASSETS |  |  |  |  |  |
Tangible assets |  | 3 |  |  |  | 1,541
CURRENT ASSETS |  |  |  |  |  |
Stock |  |  |  | 3,525 |  |
Debtors |  | 5 |  | 487 |  |
Cash at bank and in hand |  |  |  | 74,756 |  |
|  |  |  | 78,768 |  |
CREDITORS: Amounts falling due within one year |  | 6 |  | 37,115 |  |
NET CURRENT ASSETS |  |  |  |  |  | 41,653
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  |  |  |  | 43,194
PROVISIONS FOR LIABILITIES AND CHARGES |  | 7 |  |  |  | 385
NET ASSETS |  |  |  |  |  | 42,809
CAPITAL AND RESERVES |  |  |  |  |  |
Called up share capital |  | 8 |  |  |  | 100
Profit and loss account |  |  |  |  |  | 42,709
SHAREHOLDERS' FUNDS |  |  |  |  |  | 42,809
For the year ending 31/05/2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors have decided not to deliver to the registrar a copy of the company's profit and loss account.
Approved by the board on 03/02/2026 and signed on their behalf by |  |  |  |  |  |
............................. |  |  |  |  |  |
Richard Bell |  |  |  |  |  |
Director |  |  |  |  |  |

Pharma4orce Ltd

NOTES TO THE ACCOUNTS
FOR THE 386 DAY PERIOD ENDED 31/05/2025

1. ACCOUNTING POLICIES

1a. Basis Of Accounting
The accounts have been prepared under the historical cost convention.
The accounts have been prepared in accordance with FRS102 section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006 .

1b. Depreciation |  |
Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives.
Equipment |  | reducing balance 25%

1c. Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell (net realisable value). Costs, which comprise direct production costs, are based on the method most appropriate to the type of inventory class, but usually on a first-in-first-out basis. Overheads are charged to profit or loss as incurred. Net realisable value is based on the estimated selling price less any estimated completion or selling costs.
When stocks are sold, the carrying amount of those stocks is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of stocks to net realisable value and all losses of stocks are recognised as an expense in the period in which the write-down or loss occurs. The amount of any reversal of any write-down of stocks is recognised as a reduction in the amount of stocks recognised as an expense in the period in which the reversal occurs.

2. EMPLOYEES |  |  |  |  |  |
|  |  |  | 2025 |  |
|  |  |  | No. |  | No.
Average number of employees |  |  |  | - |  |

Pharma4orce Ltd

3. TANGIBLE FIXED ASSETS |  |  |  |
|  | Equipment |  | Total
|  | £ |  | £
Cost |  |  |  |
Additions |  | 1,636 |  | 1,636
At 31/05/2025 |  | 1,636 |  | 1,636
Depreciation |  |  |  |
For the 386 day period |  | 95 |  | 95
At 31/05/2025 |  | 95 |  | 95
Net Book Amounts |  |  |  |
At 31/05/2025 |  | 1,541 |  | 1,541

4. STOCK |  |  |  | 2025
|  |  |  | £
Stock comprises: |  |  |  |
Work in progress |  |  |  | 3,525
|  |  |  | 3,525

5. DEBTORS |  |  |  | 2025
|  |  |  | £
Amounts falling due within one year |  |  |  |
Prepayments |  |  |  | 487
|  |  |  | 487

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |  |  |  |
|  |  |  | 2025
|  |  |  | £
UK corporation tax |  |  |  | 18,619
VAT |  |  |  | 16,167
Directors current account |  |  |  | 2,329
|  |  |  | 37,115

Pharma4orce Ltd

7. PROVISIONS FOR LIABILITIES |  |  |  | 2025
|  |  |  | £
Deferred taxation |  |  |  | 385
|  |  |  | 385

8. SHARE CAPITAL |  |  |  | 2025
|  |  |  | £
Allotted, issued and fully paid: |  |  |  |
100 Ordinary of £1 each |  |  |  | 100
|  |  |  | 100